DALLAS, March 13 /PRNewswire/ -- BioMagnetics Diagnostics Corp. (Pink Sheets: BMGP) has been rated Speculative Buy with a price target of $1.42 by Beacon Equity Research Analyst, Lisa Springer, CFA.
The full report is available at http://www.BeaconEquity.com.
Anyone interested in receiving alerts regarding BioMagnetics Diagnostics research should email firstname.lastname@example.org with "BMGP" in the subject line.
In the report, the analyst writes, "Biomagnetics Diagnostics Corp. (BMGP) is a biotechnology company engaged in the discovery, development and marketing of new and innovative diagnostic equipment and immunoassays. The Company, through its wholly owned subsidiary, Bio-Spectrum Technologies, Inc., develops and patents potentially revolutionary diagnostic technologies.
"BMGP's flagship product, the High Throughput Screening-Magnetic Testing Platform (HTS-MTP) diagnostic system, is designed to detect any pathogen -- viral or bacterial -- using any body fluid as the testing median. It is the only system that measures viral load concomitantly with detection. Moreover, using the HTS-MTP system, multiple tests can be performed in one assay in a matter of minutes; that is several hundred percent more assays per hour than existing technologies at a fraction of the cost."
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of BioMagnetics (BMGP). Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated twenty five thousand dollars from a non-controlling third party for enrollment of BMGP in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Reuben Sushman of Beacon Equity Research is a member of the National
Association of Securities Dealers, CRD number 1755680.
Beacon Equity Research
Jeff Bishop, (469)-252-3505
http://www.BeaconEquity.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. JEFF BISHOP http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=70781
Copyright©2008 PR Newswire.
All rights reserved